Nat Rev Cardiol 2018
Disclosure of Invention The invention aims to overcome the defects in the prior art, and provides a brand new synthesis method of semaglutide, which has the advantages of simple and convenient operation, low synthesis cost, higher efficiency, realization of industrial production, higher product purity and stable product quality
For detailed insights on herbal preparations and research, refer to dedicated studies in this area
On a side note: To avoid unwanted drug interactions, a patient should not treat diabetes-related symptoms with the help of Ozempic (Semaglutide) 2 mg/1.5 ml in case of currently taking any incompatible medications, over-the-counter medicines, drink fluids, or herbal supplements
Increased toxicity of a pharmacologically active metabolite of irinotecan (SN38) has been described in patients suffering from Gilberts syndrome as UGT1A1 is the main enzyme responsible for the formation of the inactive SN38 glucuronide (Wasserman et al., 1997)